Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heat Biologics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises US$5 Million In Venture Financing 13
Heat Biologics Raises US$2.83 Million In Venture Financing 14
Partnerships 15
Selexis and Pelican Therapeutics Enter into Agreement 15
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 16
Licensing Agreements 17
University of Miami Enters into Licensing Agreement with Heat Biologics 17
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Heat Biologics Amends License Agreement with University of Michigan 22
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 23
Heat Biologics Enters into Four Licensing Agreements with University of Miami 24
Equity Offering 26
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Plans to Raise up to USD50 Million in Public Offering of Securities 27
Heat Biologics Prices Rights Offering of Shares for up to USD7.4 Million 28
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 29
Heat Biologics Raises USD7 Million in Public Offering of Shares 30
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 32
Heat Biologics Completes Underwriters’ Partial Exercise Of Over-Allotment Option For IPO Of Shares For US$27 Million 34
Acquisition 36
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 36
Heat Biologics Inc – Key Competitors 37
Heat Biologics Inc – Key Employees 38
Heat Biologics Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Nov 13, 2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update 40
May 11, 2017: Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017 41
Mar 31, 2017: Heat Biologics Reports Fiscal Year 2016 Financial Results 43
Nov 10, 2016: Heat Biologics Provides Corporate Update and Reports Third Quarter 2016 Financial Results 45
Aug 15, 2016: Heat Biologics Provides Corporate Update and Reports Second Quarter 2016 Financial Results 47
May 11, 2016: Heat Biologics Reports First Quarter 2016 Financial Results 49
Feb 18, 2016: Heat Biologics Reports Fiscal Year 2015 Financial Results 50
Corporate Communications 51
Oct 23, 2017: Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards 51
Jul 03, 2017: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics 52
Jan 04, 2017: Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer 53
Apr 25, 2016: Heat Biologics Appoints Dr. John Prendergast to Board of Directors 54
Product News 55
Jul 07, 2016: Heat Biologics Announces “Cancer Immunology Research” Publication Featuring its ComPACT Platform Technology 55
06/28/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award 56
05/19/2016: Pelican Therapeutics awarded $15.2 million to develop novel immune therapy for multiple cancers 57
03/16/2017: Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine 58
Clinical Trials 59
Mar 07, 2016: Heat Biologics Presents Positive ComPACT Preclinical Data at the Keystone Symposia 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
Heat Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heat Biologics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Heat Biologics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises US$5 Million In Venture Financing 13
Heat Biologics Raises US$2.83 Million In Venture Financing 14
Selexis and Pelican Therapeutics Enter into Agreement 15
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 16
University of Miami Enters into Licensing Agreement with Heat Biologics 17
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Heat Biologics Amends License Agreement with University of Michigan 22
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 23
Heat Biologics Enters into Four Licensing Agreements with University of Miami 24
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Plans to Raise up to USD50 Million in Public Offering of Securities 27
Heat Biologics Prices Rights Offering of Shares for up to USD7.4 Million 28
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 29
Heat Biologics Raises USD7 Million in Public Offering of Shares 30
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 32
Heat Biologics Completes Underwriters’ Partial Exercise Of Over-Allotment Option For IPO Of Shares For US$27 Million 34
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 36
Heat Biologics Inc, Key Competitors 37
Heat Biologics Inc, Key Employees 38
Heat Biologics Inc, Subsidiaries 39